Literature DB >> 12542582

Mass media release of medical research results: an analysis of antihypertensive drug prescribing in the aftermath of the calcium channel blocker scare of March 1995.

Margaret E Brunt1, Michael D Murray, Siu L Hui, Joseph Kesterson, Anthony J Perkins, William M Tierney.   

Abstract

BACKGROUND: Disclosure of medical research results to the public creates tension between lay medical reporters and the medical profession.
OBJECTIVE: To explore the early effect of media attention on the risks associated with short-acting calcium channel blockers (CCBs) for treating hypertension after publication at a national meeting and following publication.
DESIGN: Time-series analysis of prescription claims data. SETTING AND DATA SOURCE: National third-party pharmaceutical benefits manager. PATIENTS: Employed or retired persons and their families, 18 years of age or older, receiving prescription benefits from 1 of 4 national companies that contracted with the pharmaceutical benefits manager exclusively for prescription drug coverage. MEASUREMENTS: Prescription claims for antihypertensive drugs by fill date converted to a percentage of all cardiovascular drug claims. Data were grouped into weekly intervals before and immediately after the national release of negative information about CCBs on March 10, 1995 and following publication of the results on August 23, 1995.
RESULTS: The most prevalent antihypertensive drugs were diuretics (21% of cardiovascular prescription claims) and calcium channel blockers (19%). A 10% decline in prescriptions filled for CCBs occurred 4 weeks following the intense media attention. Only prescriptions for long-acting calcium channel blockers declined. Alpha-1-blocker prescriptions increased by approximately the same amount that prescriptions for CCBs declined, suggesting substitution of one drug for the other. Changes in diuretic or beta-blocker prescriptions filled were not statistically significant. No immediate change in other cardiovascular drug classes occurred following journal publication.
CONCLUSIONS: Intense media publicity regarding a controversial study measurably and unpredictably changed prescription claims.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542582      PMCID: PMC1494819          DOI: 10.1046/j.1525-1497.2003.20502.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  22 in total

1.  Sensationalism and the news media.

Authors:  W W Parmley
Journal:  J Am Coll Cardiol       Date:  1995-09       Impact factor: 24.094

2.  The Ingelfinger rule, embargoes, and journal peer review--Part 1.

Authors:  L K Altman
Journal:  Lancet       Date:  1996-05-18       Impact factor: 79.321

3.  The Ingelfinger rule, embargoes, and journal peer review--part 2.

Authors:  L K Altman
Journal:  Lancet       Date:  1996-05-25       Impact factor: 79.321

4.  The impact of media coverage on practice.

Authors:  D P Sulmasy
Journal:  J Gen Intern Med       Date:  1996-01       Impact factor: 5.128

Review 5.  Medical scientists and health news reporting: a case of miscommunication.

Authors:  M Shuchman; M S Wilkes
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

6.  The Ingelfinger Rule.

Authors:  A S Relman
Journal:  N Engl J Med       Date:  1981-10-01       Impact factor: 91.245

7.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.

Authors:  C D Furberg; B M Psaty; J V Meyer
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

8.  No magic bullets: a systematic review of 102 trials of interventions to improve professional practice.

Authors:  A D Oxman; M A Thomson; D A Davis; R B Haynes
Journal:  CMAJ       Date:  1995-11-15       Impact factor: 8.262

9.  Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.

Authors:  J Y Gillenwater; R L Conn; S G Chrysant; J Roy; M Gaffney; K Ice; N Dias
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

10.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  6 in total

1.  On the prevention and treatment of exaggeration.

Authors:  Lisa M Schwartz; Steven Woloshin
Journal:  J Gen Intern Med       Date:  2003-02       Impact factor: 5.128

2.  The impact of clinical trials on the use of hormone replacement therapy. A population-based study.

Authors:  Nancy Kim; Cary Gross; Jeptha Curtis; Glen Stettin; Stephen Wogen; Nami Choe; Harlan M Krumholz
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

3.  Average household exposure to newspaper coverage about the harmful effects of hormone therapy and population-based declines in hormone therapy use.

Authors:  Jennifer S Haas; Diana L Miglioretti; Berta Geller; Diana S M Buist; David E Nelson; Karla Kerlikowske; Patricia A Carney; Sarah Dash; Erica S Breslau; Rachel Ballard-Barbash
Journal:  J Gen Intern Med       Date:  2007-01       Impact factor: 5.128

4.  Potential of UK and US newspapers for shaping patients' knowledge and perceptions about antidiabetic medicines: a content analysis.

Authors:  Nadia Farhanah Syafhan; Gaoyun Chen; Carole Parsons; James C McElnay
Journal:  J Pharm Policy Pract       Date:  2022-10-15

5.  Media reporting of health interventions: signs of improvement, but major problems persist.

Authors:  Amanda Wilson; Billie Bonevski; Alison Jones; David Henry
Journal:  PLoS One       Date:  2009-03-18       Impact factor: 3.240

Review 6.  Towards understanding the de-adoption of low-value clinical practices: a scoping review.

Authors:  Daniel J Niven; Kelly J Mrklas; Jessalyn K Holodinsky; Sharon E Straus; Brenda R Hemmelgarn; Lianne P Jeffs; Henry Thomas Stelfox
Journal:  BMC Med       Date:  2015-10-06       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.